CY1109355T1 - Πυριμιδινες υποκατεστημενες με αρυλιο και η χρηση αυτων - Google Patents
Πυριμιδινες υποκατεστημενες με αρυλιο και η χρηση αυτωνInfo
- Publication number
- CY1109355T1 CY1109355T1 CY20091100941T CY091100941T CY1109355T1 CY 1109355 T1 CY1109355 T1 CY 1109355T1 CY 20091100941 T CY20091100941 T CY 20091100941T CY 091100941 T CY091100941 T CY 091100941T CY 1109355 T1 CY1109355 T1 CY 1109355T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- prevention
- formula
- relates
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Η εφεύρεση σχετίζεται με μια μέθοδο αγωγής διαταραχών που επηρεάζονται από τον αποκλεισμό των διαύλων του ιόντος νατρίου η οποία χρησιμοποιεί νέες υποκατεστημένες με αρύλιο ενώσεις πυριμιδίνης του Τύπου (I): ή ένα φαρμακευτικώς αποδεκτό άλας, ή μια ένωση διαλύτη με αυτές, όπου τα A, R1, R2, R3 και R4 ορίζονται στην περιγραφή. Η εφεύρεση σχετίζεται επίσης με τη χρήση ενώσεων του τύπου I για την αγωγή βλάβης των νευρώνων που ακολουθεί την σφαιρική και την εστιακή ισχαιμία, για την αγωγή ή πρόληψη νευροεκφυλιστικών καταστάσεων όπως η πλαγία μυατροφική σκλήρυνση (ALS), και για την αγωγή, την πρόληψη ή την βελτίωση τόσο του οξέος όσο και του χρονίου πόνου, ως μέσων κατά των εμβοών, ως μέσων κατά των σπασμών, και ως αντιμανιακών κατασταλτικών, ως τοπικών αναισθητικών, ως αντιαρρυθμικών και για την αγωγή ή την πρόληψη της διαβητικής νευροπάθειας.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36354402P | 2002-03-13 | 2002-03-13 | |
EP03719019A EP1483247B1 (en) | 2002-03-13 | 2003-03-13 | Aryl substituted pyrimidines and the use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1109355T1 true CY1109355T1 (el) | 2014-07-02 |
Family
ID=27805282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20091100941T CY1109355T1 (el) | 2002-03-13 | 2009-09-10 | Πυριμιδινες υποκατεστημενες με αρυλιο και η χρηση αυτων |
Country Status (27)
Country | Link |
---|---|
US (1) | US7229993B2 (el) |
EP (1) | EP1483247B1 (el) |
JP (1) | JP4473583B2 (el) |
KR (1) | KR20040099324A (el) |
CN (1) | CN1646500A (el) |
AP (1) | AP2004003152A0 (el) |
AT (1) | ATE434610T1 (el) |
AU (1) | AU2003223049A1 (el) |
BR (1) | BR0308451A (el) |
CA (1) | CA2479036A1 (el) |
CO (1) | CO5611139A2 (el) |
CR (1) | CR7526A (el) |
CY (1) | CY1109355T1 (el) |
DE (1) | DE60328087D1 (el) |
DK (1) | DK1483247T3 (el) |
EA (1) | EA200401120A1 (el) |
EC (1) | ECSP045360A (el) |
ES (1) | ES2328471T3 (el) |
IL (1) | IL163940A0 (el) |
IS (1) | IS7468A (el) |
MA (1) | MA27196A1 (el) |
MX (1) | MXPA04008901A (el) |
NO (1) | NO20044311L (el) |
PT (1) | PT1483247E (el) |
SI (1) | SI1483247T1 (el) |
TN (1) | TNSN04174A1 (el) |
WO (1) | WO2003076414A2 (el) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003008398A1 (en) * | 2001-07-16 | 2003-01-30 | Euro-Celtique S.A. | Aryl substituted thiazolidinones and the use thereof |
AR037233A1 (es) | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
CN1671672A (zh) * | 2002-07-31 | 2005-09-21 | 欧洲凯尔特股份有限公司 | 芳基取代的苯并咪唑类及其作为钠通道阻滞剂的用途 |
US20050227974A9 (en) * | 2002-08-01 | 2005-10-13 | Euro-Celtique S.A. | Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers |
US20040152696A1 (en) * | 2002-08-01 | 2004-08-05 | Euro-Celtique S.A. | 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers |
JP2007505121A (ja) * | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
WO2005099688A2 (en) | 2004-04-07 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
JP2008531710A (ja) * | 2005-03-04 | 2008-08-14 | アルスジエン・インコーポレーテツド | 神経変性疾患の調節 |
US20070135437A1 (en) * | 2005-03-04 | 2007-06-14 | Alsgen, Inc. | Modulation of neurodegenerative diseases |
PT1942898E (pt) | 2005-09-14 | 2011-12-20 | Takeda Pharmaceutical | Inibidores da dipeptidilpeptidase para o tratamento da diabetes |
JP5122462B2 (ja) | 2005-09-16 | 2013-01-16 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
EP2593434A1 (en) | 2010-07-16 | 2013-05-22 | Purdue Pharma LP | Pyridine compounds as sodium channel blockers |
WO2012035421A2 (en) | 2010-09-17 | 2012-03-22 | Purdue Pharma L.P. | Pyridine compounds and the uses thereof |
US9045435B2 (en) | 2010-10-05 | 2015-06-02 | Purdue Pharma, L.P. | Quinazoline compounds as sodium channel blockers |
CN103429571A (zh) | 2010-12-22 | 2013-12-04 | 普渡制药公司 | 作为钠通道阻断剂的取代吡啶 |
HUE034925T2 (en) | 2011-09-02 | 2018-03-28 | Purdue Pharma Lp | Pyrimidines as sodium channel blockers |
US9388137B2 (en) | 2011-10-31 | 2016-07-12 | Purdue Pharma L.P. | Quaternized amines as sodium channel blockers |
US9181185B2 (en) | 2011-10-31 | 2015-11-10 | Purdue Pharma L.P. | Heteroaryl compounds as sodium channel blockers |
US9133131B2 (en) | 2011-11-15 | 2015-09-15 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
AU2013203824A1 (en) | 2012-03-16 | 2013-10-03 | Purdue Pharma L.P. | Substituted pyridines and pryimidines as sodium channel blockers |
WO2014096941A1 (en) | 2012-12-20 | 2014-06-26 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
US9120786B2 (en) | 2013-03-04 | 2015-09-01 | Purdue Pharma, L.P. | Triazine carboxamides as sodium channel blockers |
US9637458B2 (en) | 2013-03-04 | 2017-05-02 | Jeffrey Lockman | Pyrimidine carboxamides as sodium channel blockers |
CA2939549C (en) | 2013-03-15 | 2020-08-18 | Purdue Pharma L.P. | Carboxamide derivatives and use thereof |
US9359330B2 (en) | 2013-08-26 | 2016-06-07 | Purdue Pharma L.P. | Substituted piperidines as sodium channel blockers |
CN105612152A (zh) | 2013-08-26 | 2016-05-25 | 普渡制药公司 | 氮杂螺[4.5]癸烷衍生物及其用途 |
US9828348B2 (en) | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
US9340504B2 (en) | 2013-11-21 | 2016-05-17 | Purdue Pharma L.P. | Pyridine and piperidine derivatives as novel sodium channel blockers |
WO2015094443A1 (en) * | 2013-12-20 | 2015-06-25 | Purdue Pharma L.P. | Pyrimidines and use thereof |
EP3087059B1 (en) | 2013-12-23 | 2020-04-29 | Purdue Pharma L.P. | Indazoles and use thereof |
US9695144B2 (en) | 2013-12-23 | 2017-07-04 | Purdue Pharma L.P. | Dibenzazepine derivatives and use thereof |
WO2015102682A1 (en) | 2013-12-30 | 2015-07-09 | Purdue Pharma L.P. | Pyridone-sulfone morphinan analogs as opioid receptor ligands |
CN106061944A (zh) | 2014-01-24 | 2016-10-26 | 普渡制药公司 | 吡啶类和嘧啶类物质及其用途 |
CN106103422B (zh) | 2014-02-12 | 2020-09-18 | 普渡制药公司 | 异喹啉衍生物及其用途 |
US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
EP3139921A4 (en) | 2014-05-06 | 2018-02-14 | Purdue Pharma L.P. | Benzomorphan analogs and use thereof |
MA40171A (fr) | 2014-06-13 | 2017-04-19 | Purdue Pharma Lp | Dérivés d'azamophinan et leur utilisation |
EP3154971A4 (en) | 2014-06-13 | 2017-11-01 | Purdue Pharma L.P. | Heterocyclic morphinan derivatives and use thereof |
US9763955B2 (en) | 2015-02-19 | 2017-09-19 | Purdue Pharma L.P. | Methods and compositions for decreasing gastric emptying |
WO2018125716A1 (en) | 2017-01-02 | 2018-07-05 | Purdue Pharma L.P. | Morphinan derivatives and use thereof |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1122533B (de) | 1959-04-18 | 1962-01-25 | Knoll Ag Chemischer Fabriken | Verfahren zur Herstellung basisch substituierter 4-Amino-6-hydroxypyrimidine |
MA18829A1 (fr) | 1979-05-18 | 1980-12-31 | Ciba Geigy Ag | Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique |
US4492792A (en) * | 1982-02-04 | 1985-01-08 | Ube Industries, Ltd. | Process for preparing 4-amino-5-dialkoxy-methylpyrimidine derivatives |
GB8909560D0 (en) * | 1989-04-26 | 1989-06-14 | Smith Kline French Lab | Chemical compounds |
EP0555478A4 (en) * | 1990-08-31 | 1993-11-18 | Nippon Shinyaku Company, Limited | Pyrimidine derivative and medicine |
DE4124942A1 (de) * | 1991-07-27 | 1993-01-28 | Thomae Gmbh Dr K | 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
JPH0558997A (ja) | 1991-09-04 | 1993-03-09 | Mitsubishi Kasei Corp | チオカルバモイルアセトニトリル誘導体 |
US5232945A (en) * | 1992-07-20 | 1993-08-03 | Pfizer Inc. | 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives |
KR950703539A (ko) | 1992-09-28 | 1995-09-20 | 알렌 제이. 스피겔 | 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications) |
WO1994008975A1 (en) | 1992-10-16 | 1994-04-28 | Nippon Soda Co., Ltd. | Pyrimidine derivative |
CN1109687A (zh) | 1993-05-13 | 1995-10-04 | 日本钢管株式会社 | 嘧啶衍生物及医药组合物 |
GB2281295A (en) * | 1993-08-26 | 1995-03-01 | Zeneca Ltd | (2-Fluoroethyl) thio-substituted pyrimidines as nematicides |
US5569655A (en) * | 1993-09-14 | 1996-10-29 | Sterling Winthrop Inc. | Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof |
US5602156A (en) * | 1993-09-17 | 1997-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | Method for inhibiting metalloproteinase expression |
US5744492A (en) * | 1993-09-17 | 1998-04-28 | United States Of America | Method for inhibiting angiogenesis |
EP0724573A1 (en) | 1993-10-20 | 1996-08-07 | PHARMACIA & UPJOHN COMPANY | Pyrimidinones as antiarthritic and anti-inflammatories |
US5795905A (en) | 1995-06-06 | 1998-08-18 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
US5874440A (en) * | 1995-06-07 | 1999-02-23 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives |
GB9525296D0 (en) * | 1995-12-11 | 1996-02-07 | Merck Sharp & Dohme | Therapeutic agents |
DZ2805A1 (fr) | 1998-06-02 | 2005-01-30 | Cadus Pharmaceutical Corp | Composition à pyrroloÄ2,,3dÜ pyrimidine et leurs usages. |
PT1173169E (pt) * | 1999-03-26 | 2010-08-19 | Euro Celtique Sa | Pirazoles, imidazoles, oxazoles, tiazoles e pirroles substituídos com arilo |
CO5210940A1 (es) | 1999-05-04 | 2002-10-30 | Novartis Ag | Compuestos plaguicidas derivados de pirimidina y composiciones que los contienen |
BR0012984A (pt) | 1999-08-04 | 2002-07-16 | Millennium Pharm Inc | Método para tratar um estado associado com o mc4-r em um mamìfero, composto de ligação ao mc4-r, e, composição farmacêutica |
DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
ATE335489T1 (de) | 1999-12-02 | 2006-09-15 | Osi Pharm Inc | Für adenosin a3, a2a und a3 rezeptoren spezifische verbindungen und deren verwendungen |
AR029489A1 (es) * | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
AU4589701A (en) * | 2000-03-24 | 2001-10-08 | Cocensys Inc | Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof |
KR20020084278A (ko) * | 2000-03-31 | 2002-11-04 | 코센시스 인크 | 항경련제 및 나트륨 통로 차단제로서의 아미노피리딘과이의 용도 |
WO2003008398A1 (en) * | 2001-07-16 | 2003-01-30 | Euro-Celtique S.A. | Aryl substituted thiazolidinones and the use thereof |
AR036873A1 (es) * | 2001-09-07 | 2004-10-13 | Euro Celtique Sa | Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento |
AR037233A1 (es) * | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
-
2003
- 2003-03-13 WO PCT/IB2003/001837 patent/WO2003076414A2/en active Application Filing
- 2003-03-13 DE DE60328087T patent/DE60328087D1/de not_active Expired - Lifetime
- 2003-03-13 EP EP03719019A patent/EP1483247B1/en not_active Expired - Lifetime
- 2003-03-13 CA CA002479036A patent/CA2479036A1/en not_active Abandoned
- 2003-03-13 DK DK03719019T patent/DK1483247T3/da active
- 2003-03-13 ES ES03719019T patent/ES2328471T3/es not_active Expired - Lifetime
- 2003-03-13 MX MXPA04008901A patent/MXPA04008901A/es unknown
- 2003-03-13 AP APAP/P/2004/003152A patent/AP2004003152A0/en unknown
- 2003-03-13 JP JP2003574634A patent/JP4473583B2/ja not_active Expired - Fee Related
- 2003-03-13 KR KR10-2004-7014305A patent/KR20040099324A/ko not_active Application Discontinuation
- 2003-03-13 BR BR0308451-5A patent/BR0308451A/pt not_active Application Discontinuation
- 2003-03-13 AU AU2003223049A patent/AU2003223049A1/en not_active Abandoned
- 2003-03-13 IL IL16394003A patent/IL163940A0/xx unknown
- 2003-03-13 SI SI200331664T patent/SI1483247T1/sl unknown
- 2003-03-13 US US10/386,483 patent/US7229993B2/en not_active Expired - Lifetime
- 2003-03-13 EA EA200401120A patent/EA200401120A1/ru unknown
- 2003-03-13 AT AT03719019T patent/ATE434610T1/de active
- 2003-03-13 CN CNA038083833A patent/CN1646500A/zh active Pending
- 2003-03-13 PT PT03719019T patent/PT1483247E/pt unknown
-
2004
- 2004-09-10 TN TNP2004000174A patent/TNSN04174A1/en unknown
- 2004-09-24 IS IS7468A patent/IS7468A/is unknown
- 2004-10-11 MA MA27905A patent/MA27196A1/fr unknown
- 2004-10-12 NO NO20044311A patent/NO20044311L/no unknown
- 2004-10-12 CO CO04101907A patent/CO5611139A2/es not_active Application Discontinuation
- 2004-10-12 EC EC2004005360A patent/ECSP045360A/es unknown
- 2004-10-13 CR CR7526A patent/CR7526A/es not_active Application Discontinuation
-
2009
- 2009-09-10 CY CY20091100941T patent/CY1109355T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US7229993B2 (en) | 2007-06-12 |
BR0308451A (pt) | 2005-01-11 |
WO2003076414A2 (en) | 2003-09-18 |
CA2479036A1 (en) | 2003-09-18 |
WO2003076414A3 (en) | 2003-12-24 |
AU2003223049A1 (en) | 2003-09-22 |
EA200401120A1 (ru) | 2005-02-24 |
JP4473583B2 (ja) | 2010-06-02 |
DE60328087D1 (de) | 2009-08-06 |
CR7526A (es) | 2008-08-12 |
EP1483247B1 (en) | 2009-06-24 |
JP2005526069A (ja) | 2005-09-02 |
MA27196A1 (fr) | 2005-01-03 |
EP1483247A2 (en) | 2004-12-08 |
ES2328471T3 (es) | 2009-11-13 |
NO20044311L (no) | 2004-12-10 |
TNSN04174A1 (en) | 2007-03-12 |
MXPA04008901A (es) | 2004-11-26 |
AP2004003152A0 (en) | 2004-12-31 |
IL163940A0 (en) | 2005-12-18 |
US20030236273A1 (en) | 2003-12-25 |
KR20040099324A (ko) | 2004-11-26 |
DK1483247T3 (da) | 2009-08-17 |
ATE434610T1 (de) | 2009-07-15 |
PT1483247E (pt) | 2009-08-18 |
SI1483247T1 (sl) | 2009-12-31 |
IS7468A (is) | 2004-09-24 |
ECSP045360A (es) | 2005-01-03 |
CO5611139A2 (es) | 2006-02-28 |
CN1646500A (zh) | 2005-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1109355T1 (el) | Πυριμιδινες υποκατεστημενες με αρυλιο και η χρηση αυτων | |
CY1105053T1 (el) | Υποκατεστημενες ομοιαζουσες με ινδολιζινη ενωσεις και μεθοδοι χρησης | |
EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
BR0205829A (pt) | Novas aminas como ligantes dos receptores de histamina-3 e suas aplicações terapêuticas | |
EA200200509A1 (ru) | Новые производные бензоимидазола, используемые в качестве антипролиферативного средства | |
EA200200306A1 (ru) | Трициклические ингибиторы поли(адф-рибозо)полимераз | |
ECSP055719A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
DK1346041T3 (da) | Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom | |
CY1110809T1 (el) | Πυριδινες, πυριμιδινες, πυραζινες και τριαζινες υποκατεστημενες με αρυλιο και η χρηση αυτων | |
CY1108720T1 (el) | Διαρυλ υποκατεστημενα τριαζολια ως αναστολεις διαυλου νατριου | |
CY1115417T1 (el) | Τροποποιημενα 2’ και 3’-νουκλεοζιτικα προφαρμακα για θεραπεια μολυνσεων απο flaviviridae | |
CY1106645T1 (el) | Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος | |
CY1110580T1 (el) | Νεα παραγωγα βενζοϊμιδαζολιου χρησιμα ως αντιπολλαπλασιαστικοι παραγοντες | |
BRPI0414254A (pt) | composição farmacêutica, e, métodos para fabricar uma composição farmacêutica, para o tratamento de pelo menos uma doença e para controlar a taxa de dissolução de uma formulação | |
ATE407928T1 (de) | Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung | |
DE602004006165D1 (de) | Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors | |
BRPI0417820A (pt) | heterociclos azabicìclicos como moduladores de receptor canabinóide | |
DE602004031037D1 (de) | Heterocyclische inhibitoren von mek | |
CY1109490T1 (el) | Τρικυκλικοι τροποποιητες πυρηνικων υποδοχεων στεροειδων ορμονων | |
CY1117094T1 (el) | Παραγωγα 2-φαινυλαιθυλαμινης ως τροποποιητες του διαυλου ασβεστιου και/ή νατριου | |
BR9801157A (pt) | Derivados de adamantano substituìdos por flúor. | |
MX2022013650A (es) | Imidazopirimidinas como moduladores de il-17. | |
CY1106225T1 (el) | Διαδικασια για την παρασκευη της 2-μεθυλ πιπepαζινης | |
EA200300882A1 (ru) | Способ лечения демиелинизирующих заболеваний или состояний | |
PT1109560E (pt) | Compostos uteis como inidores de aicarft |